Sanofi could try to differentiate Zantac 360 among histamine-2 blockers in the OTC heartburn remedy category by qualifying and modifying its “#1 doctor recommended” claim that an industry self-regulation group’s appeals panel says it didn’t support.
The French firm asked BBB National Programs Inc.’s National Advertising Review Board to consider using a claim of “#1 doctor recommended H2 active ingredient” featuring the disclaimer “based on generic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?